Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (918 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: stagebiopsycellinjurytransplant
  Phrases that lowered it: open labelhistoryrandomized openassess20
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports marked serious: 45.9% (lowers risk) · Drug's FDA history
• Phase: 1 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 6.9% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Maximum age: 65 (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Has a data monitoring committee: No (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation NCT01919346 · started 2013 · scored riskier than 94% of active trials terminated
• Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) NCT02145182 · started 2014 · scored riskier than 90% of active trials completed
• Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor NCT01567085 · started 2012 · scored riskier than 73% of active trials completed
• Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant NCT01106027 · started 2010 · scored riskier than 82% of active trials terminated
• A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant NCT01403389 · started 2011 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.